Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Cytodesign

Financiado

Novel engineered cytokines for human therapy

Cytokines are biomolecules of great potential interest for human therapy. They modulate the immune system and play an important role in cancer, inflammation, immune response and tissue regeneration. Despite their great potential,... ver más

30/06/2024

FUNDACIO PRIVADA C...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 50K€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

FUNDACIO PRIVADA CENTRE DE R...

150.00K€ | Lider

Proyectos interesantes

PTQ2018-009932 Investigación y lanzamiento de nuevas formulaciones de pépti... 66K€ Cerrado

SAF2015-72617-EXP REPROGRAMACION Y REGENERACION TISULAR A PARTIR DE MICROVESIC... 48K€ Cerrado

Smart ProTcell Smart Immune ProTcell: first-in-class allogeneic thymus empo... 4M€ Cerrado

BES-2017-079676 TERAPIAS BASADAS EN GLICOMIMETICOS PARA EL TRATAMIENTO DE EN... 93K€ Cerrado

PID2020-113910RB-I00 CONDICIONAMIENTO BIOFISICO DE CELULAS MADRE/ESTROMALES MESEN... 218K€ Cerrado

EQC2019-005948-P Unidad para investigación y desarrollo en terapia celular av... 143K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 23 meses Fecha Inicio: 2022-07-08
Fecha Fin: 2024-06-30

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA

TRL 4-5 | 50K€

Presupuesto del proyecto 150K€

Descripción del proyecto Cytokines are biomolecules of great potential interest for human therapy. They modulate the immune system and play an important role in cancer, inflammation, immune response and tissue regeneration. Despite their great potential, there are only a handful of cytokines approved for therapeutic purposes. This is because many of them can have adverse side effects as they usually target different cell types, which adds to their low serum half-life, high production costs, or lack of physiological efficacy. Different methods have been proposed to improve the pharmacodynamics and pharmacokinetics of selected cytokines. However, other properties do also need improvement, such as achieving effective local concentration at the target site; promoting the right activity in cytokines with dual functionality and decreasing toxicity by removing binding to unwanted cell types. To help solving these issues, we have developed a new protein design strategy that can be applied to all helix-bundle cytokines, many of which have been shown to be therapeutically relevant. The resulting products are uniquely modified cytokines with improved properties. Amongst such properties, our products show increase stability, higher affinity and specificity for their target receptors and should have reduced toxicity, all of which translate into greater safety and efficacy. We have initial evidence both (in vitro and in vivo) of the superiority of our designs over conventional cytokines, and in this project we will fully validate our technological platform and advance in the development of a business plan following the advice of several venture capital and pharma companies contacted to date, with the idea of laying the basis for the creation of a new start-up company.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores